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1:30 p.m.
2802-3 Cutting Balloons in the Management of Pediatric 
Systemic Venous Stenosis
Henri Justino, Alan W. Nugent, Christopher J. Petit, Jose G. Diez, Frank F. Ing, Texas 
Children’s Hospital, Houston, TX, Baylor College of Medicine, Houston, TX
Background: Systemic venous thrombosis in young children is commonly complicated 
by the development of localized venous strictures (VS) and/or total occlusion. VS, defined 
as non-compliant lesions resistant to high-pressure balloon angioplasty (HPBA), therefore 
result in ineffective angioplasty and also limit the effectiveness of stenting. Cutting balloon 
angioplasty (CBA) is used to treat resistant lesions in systemic and pulmonary arteries, 
but safety & efficacy in systemic veins in young children has not been reported.
Methods: Pts undergoing catheterization (cath) to treat systemic venous stenoses were 
identified. Results of CBA on VS resistant to HPBA were analyzed.
Results: From 1/2006 to 10/2007, 32 individual VS (in 10 pts, 11 caths) requiring CBA 
were identified. Median (range) age & weight were 10.6 (1.8-50.6) mos & 7.6 (3.3-18.5) 
kg respectively. VS were located in the internal jugular (11), innominate (12), superior 
vena cava (7), subclavian (1) & common iliac (1) veins. Median lesion diameter was 1.2 
(0-4.5) mm. Total occlusions (12 lesions in 5 pts) were recanalized using guidewires (9), 
transseptal needles (1), or radiofrequency energy (2). HPBA produced a resistant waist 
measuring 3.6 (0.5-6) mm (p<0.001 compared to baseline). Initial CB diameter used was 
5 (2.5-7) mm. Additional CBA ± HPBA (with stent implantation in 17) achieved a final 
vessel diameter of 5.5 (2-9) mm (p<0.001 compared to diameter of HPBA waist). All CB 
angioplasties were acutely successful, with no hemorrhagic or other patient complications. 
Vessel dissection was seen in 1 lesion, successfully treated with stent implantation. 
At follow-up imaging, 7 of 15 lesions (47%) which did not undergo immediate stenting 
developed restenosis. However, all stented lesions (17) remained patent. Immediate 
stenting had a significantly greater patency rate (p<0.001). 5 of 7 restenoses underwent 
stent implantation at a subsequent cath. At mean f/u of 4 (±5.6) mos, 30/32 remained 
patent (94%).
Conclusions: VS, although resistant to HPBA, are highly responsive to CBA. CBA 
appears to be safe in systemic venous stenoses even in young children. Immediate 
stenting is associated with a significantly greater patency rate.
1:45 p.m.
2802-4 Aortic Injury as a Complication of Neonatal Aortic 
Valvuloplasty: Incidence and Risk Factors
Erin Chong, David Brown, John Keane, James Lock, Audrey Marshall, Children’s 
Hospital Boston, Boston, MA
Background: Transcatheter balloon dilation of critical aortic stenosis is routinely 
performed without recognized complication. A recent case of aortic injury following 
intervention at our institution prompted a review of our entire experience. We sought to 
determine the incidence of aortic injury in neonatal balloon valvuloplasty, and to identify 
any risk factors.
Methods: This retrospective study included all patients < 2 months of age who underwent 
balloon aortic valvuloplasty at our institution from 1985-2006. We defined aortic injury as an 
intimal flap, dissection, or vessel rupture as diagnosed by angiography, echocardiography, 
or direct inspection. One author read all of the postprocedural echocardiograms, and two 
authors independently reviewed the angiography. All procedural and pathology reports 
were reviewed. Patient and procedural variables were analyzed.
Results: Of 175 procedures performed, aortic injury was diagnosed in 27 (15%). Injury 
was diagnosed by echocardiography in 25 cases, and angiographically in 13 cases. 
Nearly all injuries consisted of aortic intimal flaps, which occurred most commonly in the 
transverse arch. Aortic injury was associated with balloon:annulus ratio (1.01 in those with 
injuries vs. 0.94 in those uninjured, p=0.034) and number of balloon dilations performed 
(3 vs. 2, p=0.018). Other variables such as patient age, size, and BSA, type and approach 
of catheter, aortic annulus and ascending aorta sizes and Z-scores, and duration of case 
did not appear to be associated with injury.
Conclusions: Aortic injury, specifically creation of an intimal flap, is an underrecognized 
complication of neonatal balloon valvuloplasty, occurring in 15% of cases even in the 
recent era. Higher balloon to annulus ratio and greater number of balloon dilations are 
associated with this injury. The clinical sequelae of these flaps are unknown, but may 
include aortic or brachiocephalic obstruction, and thromboembolic risk.
2:00 p.m.
2802-5 Adverse Events Attributable to Contrast Administration 
in Pediatric Cardiac Catheterization
Selvi Senthilnathan, Kimberlee Gauvreau, James E. Lock, Lisa Bergersen, Children’s 
Hospital Boston, Boston, MA
Background: Adverse events related to contrast exposure in pediatrics such as allergic 
reactions, focal and generalized seizures, nephropathy, transient hypothyroidism and skin 
reactions have been reported, but the incidence of these events and their relationship to 
contrast dose has not been studied in the pediatric population.
Methods To identify adverse events related to contrast we used a single institution 
prospectively gathered congenital cardiac catheterization adverse event database. 
Cases were limited to children less than 18 years of age and excluded if contrast was not 
administered. Patient and procedural characteristics among cases in the top quartile of 
contrast administration were compared to the remaining cases. All adverse events were 
reviewed and classified as not related, possibly related, or definitely related to contrast 
administration. The 50 cases with the maximum contrast dose administration were 
reviewed for the occurrence of events possibly related to contrast exposure.
Results We identified 2321 cases requiring contrast [median 3.9 cc/kg (interquartile 
range: 2.0-6.0)] in children between 1/04 and 1/07. The following patient and procedural 
characteristics were more common among patients receiving high dose contrast (top 
quartile): age < 1 year old (51% vs 23%), weight < 10 kg (66% vs 29%), complex two 
ventricle disease (56% vs 35%), procedures with higher baseline risk for complications 
(57% vs 26%), and procedure time > 2 hours (67% vs 28%), all p<0.001. Among 650 
adverse events recorded at the time of the procedure or in follow-up, a definitely or 
possible contrast related event occurred in 2 of 2321 (0.09%) cases. In 1 of 3 adverse 
neurologic events, contrast exposure may have contributed to the event. In another case, 
a transient increase in BUN and creatinine occurred after the case. For the 50 patients 
receiving the most contrast, there were no contrast related events identified in the medical 
record review.
Conclusion In a large volume pediatric cardiac catheterization lab high dose (exceeding 
the manufacturer recommendations) contrast was administered in a quarter of cases; 
however, adverse consequences related to contrast exposure were exceedingly rare.
2:15 p.m.
2802-6 Results of FDA Sentinal Study of Nit-Occlud PDA 
Occluder
John W. Moore, Alexander J. Javois, Carl Y. Owada, John P. Cheatham, Nit-Occlud 
Investigator Group, Rady Children’s Hospital, San Diego, CA, University of California, 
San Diego, CA
Background: Interventional occlusion of patent ductus arteriosus (PDA) is standard 
treatment for non-neonates with PDA. Gianturco coils are used “off label” for occlusion 
of restrictive PDA, but have not been well studied. The Nit-Occlud PDA Occluder (pfm 
Medical, Cologne, Germany) is a nitinol spiral coil with a “cone-in-cone” configuration and 
a controlled delivery system. 
Methods: A Food and Drug Administration (FDA) supervised, prospective, multi-center, 
single arm study with objective performance criteria was performed to determine efficacy 
and safety of the Nit-Occlud device for PDA occlusion. Inclusion criteria included age 
> 6 months, weight > 5 Kg, and PDA minimum diameter < 4 mm. 340 patients were 
enrolled. Mean PDA minimum diameter was 1.94 mm. Mean ratio of pulmonary to 
systemic blood flow was 1.48. One year efficacy results were clinical and echo closure. 
Echo closure was certified by a core echo lab. One year safety results were adjudicated 
by a data safety monitoring board. Objective performance criteria were recommended by 
a multiorganizational advisory panel to the FDA. 
Results: Procedural technical success was 96.8% (329/340). Efficacy results were 
clinical closure 99% (298/301) and echo closure 97% (290/299). Safety results were no 
deaths and adverse event rate 4.9% (15/305). All adverse events resolved spontaneously 
or with limited non-surgical treatment. All efficacy and safety results exceeded objective 
performance criteria. 
Conclusions: The study demonstrates that the Nit-Occlud PDA Occluder is safe and 
effective for occlusion of PDA with minimun diameter less than 4 mm.
IV.ORAL CONTRIBUTIONS
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2804-3 Pulmonary Artery Interventions and Development 
Following Sano Modification of the Norwood Procedure
Alvaro Galindo, Amelia Vasquez, Marco Ricci, Eliot Rosenkranz, University of Miami 
School of Medicine, Miami, FL, University of Nevada School of Medicine, Las Vegas, NV
Background: Care of newborns with hypoplastic left heart syndrome (HLHS) or other 
physiologic equivalent anatomies has been challenging. Sano re-introduced a modification 
of the Norwood procedure using a shunt from the right ventricle (RV) to the pulmonary 
artery (PA). Theoretical advantages include better post-operative balance between 
systemic and pulmonary circulations and decreased diastolic run-off resulting in improved 
coronary and cerebral circulation. Theoretical disadvantages include the long-term effect 
on myocardial dysfunction and the effect of the RV to PA shunt on the development of the 
PA’s. Methods: To understand the impact that the RV to PA shunt has on the PA anatomy 
we reviewed retrospectively all patients undergoing the Sano modification at a single 
institution from 10/03 to 6/06. Nakata Index (NI) was calculated from angiographic derived 
measurements of pulmonary arteries. 16 patients underwent the Sano modification. 9 had 
HLHS, 5 had double-outlet right ventricle and 2 had unbalanced AV canals. There were 3 
early deaths (81% survival stage I). The remaining 13 patients are the basis of this study. 
Results: 3 patients (23%) underwent placement of a stent in the Sano shunt. 1 patient 
required bilateral PA stent placement in the immediate post-operative period. 5 patients 
(38%) underwent PA stent placement following the Glenn shunt. Overall 62% required 
stent placement in either the PA or Sano shunt (one patient required both). The mean 






NI was 145.8 mm2/m2 (range 65.7-262.6 mm2/m2). There was a statistically significant 
difference between the PA NI and the surgical technique used to create the anastomosis 
between the Sano shunt and the PA (P-value 0.02). With a direct anastomosis the mean 
NI was 110.9, when an autologous pericardial patch was employed the mean NI was 
121.9 mm2/m2 but in those in whom a patch of PA homograft was used the mean NI was 
172.6 mm2/m2. The most drastic effect on the development of the branch PA’s was in the 
3 patients who underwent stent placement in the Sano shunt (mean NI 272.6 mm2/m2, 
p-value< 0.001).
Conclusions: Optimal PA development following the Sano procedure can result from 
techniques that relieve PA anastomotic stenosis and improve shunt patency.
10:45 a.m.
2804-4 Prominent Eustachian Valve and Large Chiari’s Network 
Mediate Both Migraine and Paradoxical Embolism: An 
Intracardiac Echocardiographyic Study
Gianluca Rigatelli, Fabio Dell’Avvocata, Jr., Massimo Giordan, Jr., Silvio Aggio, Jr., 
Paolo Cardaioli, Sr., Section of Adult Congenital and Adult Heart Disease, Rovigo 
general Hospital, Rovigo, Italy
Background: Migraine affected a quite large portion of patients with patent foramen 
ovale (PFO). Prominent Eustachian valve (EV) and Chiari’s Network (CN) have been 
suggested as anatomical factors predisposing to paradoxical embolism but their role in 
patients with migraine has not been estsblished. We sought to prospectively assess the 
prevalence of EV and CN as assessed by intracardiac echocardiography (ICE) in patients 
with migraine submitted to PFO transcatheter closure in order to investigate their potential 
role in migraine -PFO connection.
Methods: Over a 36-months period, We prospectively enrolled 70 consecutive patients 
(mean age 37±12. 5 years, 48 female) with previous stroke referred to our centre for PFO 
catheter-based closure. Migraine with (MwA) and without aura (MwoA) were diagnosed 
according to the International Headache Society criteria and Migraine Disability Assessment 
Score (MIDAS). On ICE study performed in the aortic valve plane and 4-chamber plane 
view, prominent EV was defined as a valve with thickness > 1 mm that protrudes for at least 
10 mm within the right atrium from the border of the inferior vena cava. A large CN was 
defined as EV with thickness < 1 mm and filamentous appearance.
Results: After ICE study and measurements, a prominent EV or CN were diagnosed 
on ICE in 58 patients (82.8%): 100% in MwA-patients, 60% in MwoA-patients (p<0.001) 
and in 55.5% of patients with no migraine. Patients with EV and CN had statistically more 
frequently a curtain pattern on TC Doppler, a larger right-to-left shunt, more recurrent 
cerebral paradoxical embolism before closure, and a higher preoperative MIDAS score. 
After a mean follow up of 18.9±4.8 months mean in patients with EV/CN the mean MIDAS 
score decreased 30±5.8 to 4±2.1 compared to 12±5.0 to 5±2.1 in patients without EV 
and CN (p< 0.03).
Conclusions: This study suggests that EV and CN have a deep impact on the 
pathophysiology of both migraine with aura and paradoxical embolism: EV, CN should 
be considered as adjunctive risk factors for paradoxical embolism in the decision-making 
process involving both symptomatic and asymptomatic PFO patients.
Comparison of clinical and functional parameters between patients with and without EV/CN.
Prominent EV or CN No prominent EV or CN p
Curtain pattern on TC-D 25/58 (43.1%) 0/12 (0%) <0.01
Large Shunt on TEE 40/58 (68.9%) 2/12 (16.6%) <0.001
> 2 ischemic strokes 31/58 (53.4%) 2/12 (16.6) 0.03
11:00 a.m.
2804-5 In Vivo Redilation of Covered Stents for Coarctation of 
the Aorta: An Animal Study
Daniel S. Levi, Brent M. Gordon, Michael C. Fishbein, Mattel Children’s Hospital at 
UCLA, Los Angeles, CA
Background: The majority of patients treated for coarctation of the aorta are growing 
children. The feasibility of redilation of covered stents to adult sizes in the treatment of 
coarctation must be demonstrated before these devices can be safely used in growing 
patients.
Methods: Atrium iCAST PTFE covered stents were deployed in the descending aorta of 
eight 17-19 kg swine. Five of the eight pigs also had identical uncovered stents deployed 
in a separate location in the thoracic aorta as controls. Angiograms were performed 
before and after deployment and at recatheterization. All pigs were recatheterized after 
100 days for redilation of the stents to 14-16 mm. Half the pigs were sacrificed 40-50 days 
after this time point; the remaining four animals were allowed to grow for another 75-113 
days and were then recatheterized with redilation of the stents to 18-20 mm.
Results: All stents were deployed without complications. At the final dilation, animals 
had grown to greater than five times their initial weight. Covered stents were noted to 
recoil to 90% the diameter of the balloon. Both covered and uncovered stents could be 
successfully dilated from an initial diameter of 10.1-12.2 mm to 13.2-18.2 mm for covered 
stents and 15.8-21 mm for uncovered stents(dilations were limited only by the size of 
the adjacent aorta and stent recoil after maximal dilation). There was no gradient across 
either type of stent on recatheterization. The covered stents consistently recoiled slightly 
after maximal dilation and always required significantly higher pressures (>10atm) for 
redilation. Gross damage to the aorta was noted only in two animals in which stents were 
dilated to >10% the diameter of the native aorta. No stents manifested foreshortening of 
more than 25% with dilation by balloons of up to 20 mm.
Conclusions: Atrium iCAST PTFE covered stents and uncovereded stents could be 
successfully dilated in vivo from 10-12 mm to as much as 18-21 mm. Redilation of PTFE 
covered stents did required use of high pressure balloons and covered stents did have 
significant recoil but no foreshortening.
11:15 a.m.
2804-6 Pulmonary Artery Stents: Long-Term Follow-up
Mark Law, Pirouz Shamszad, Charles Mullins, John Breinholt, Henri Justino, Alan 
Nugent, Christopher Petit, Frank Ing, Baylor College of Medicine, Houston, TX
Background: Pulmonary artery (PA) stents (S) in congenital heart disease are effective in 
relieving stenoses in the short term. No long term data exist.
Methods: Patients (pts) with PA S (1989-92) were included. Catheterization, echocardiogram 
& latest clinical follow up (f/u) were evaluated. Percent (%) stenosis was defined by 
comparison of minimal to distal diameter. Data is presented as mean ± standard deviation.
Results: 52 pts (82 S) were identified. Diagnoses included tetralogy of Fallot (34), single 
ventricle (5) & others (13). Age of S placement was 11.8±6.0 years (yr) with f/u of 13.1±2.5 
yr. There were 11 moderate/severe procedural complications & 1 early death. During the 
late f/u period, 5 pts died due to underlying congenital heart disease & 1 was stent related 
(RPA to aorta dissection during redilation 6 yr post S implant). 4 additional major late 
complications were S fractures at 5.0-6.5 yr post placement (3) & giant RPA aneurysm 
(1). Cath f/u for 35 pts at 6.6±4.0 yr required 1±1 further dilations/stent. Pre S minimum 
diameter was 4.7±1.8 mm increasing to a final size of 13.4±2.4 mm (p<0.001). Initial % 
stenosis was 62±13% decreasing to a final of 12±11% (p<0.001). Higher initial gradient & 
% stenosis were associated with a final S diameter of <14 mm (p<0.05), but younger age 
at initial S placement was not a factor. Echo data for 38 pts at 12.9±2.6 yr showed normal 
RV function in 25, depressed in 8 (mild 5, moderate 2, severe 1) & unknown in 5. RV size 
was normal in 5 & dilated in 33 (mild 18, moderate 13, severe 2). Clinic data for 43 pts at 
13.2±2.4 yr demonstrated 39 pts (90%) are asymptomatic with a NYHA class of I or II & 4 
pts (10%) with NYHA class III symptoms. Surgical intervention was required for 7 pts during 
the f/u period (5 RV-PA conduit, 2 Fontan revision), but none for PA stenosis alone.
Conclusion: PA S dilated to adult size are effective in relieving PA stenoses, preserving RV 
function & avoiding surgery. Higher pre S gradient & % stenosis are associated with smaller 
final S diameters; however, younger age at S placement is not a risk factor, confirming 
further dilation to accommodate somatic growth is possible. Patients remain symptom free 
& no further intervention on the branch PA is necessary at adult size.
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